Jean-Sebastien Aucoin

Selective cholinergic denervation, independent from oxidative stress, in a mouse model of Alzheimer’s disease

Jean-Sebastien Aucoin, PeiHao Jiang, Nicolas Aznavour et al. · Neuroscience · 2005 · 66 citations

Life Sciences, Neurobiology, Neuroscience +17

OA04.02 CheckMate 817: First-Line Nivolumab + Ipilimumab in Patients with ECOG PS 2 and Other Special Populations with Advanced NSCLC

Fabrice Barlési, Clarisse Audigier-Valette, Enriqueta Felip et al. · Journal of Thoracic Oncology · 2019 · 48 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +5

CheckMate 649: A randomized, multicenter, open-label, phase III study of nivolumab (NIVO) + ipilimumab (IPI) or nivo + chemotherapy (CTX) versus CTX alone in patients with previously untreated advanced (Adv) gastric (G) or gastroesophageal junction (GEJ) cancer.

Markus Moehler, Yelena Y. Janjigian, Antoine Adenis et al. · Journal of Clinical Oncology · 2018 · 30 citations

Medicine, Pharmacology, Cancer Pharmacology +5

Checkmate 649: A randomized, multicenter, open-label, phase 3 study of nivolumab (Nivo) plus ipilimumab (Ipi) versus oxaliplatin plus fluoropyrimidine in patients (Pts) with previously untreated advanced or metastatic gastric (G) or gastroesophageal junction (GEJ) cancer.

Yelena Y. Janjigian, Antoine Adenis, Jean-Sebastien Aucoin et al. · Journal of Clinical Oncology · 2017 · 23 citations

Medicine, Oncology, Pharmacology +17

Nivolumab Plus Low-Dose IPILIMUMAB as First-Line Treatment of Advanced NSCLC: Overall Survival Analysis of Checkmate 817

Fabrice Barlési, Clarisse Audigier-Valette, Enriqueta Felip et al. · Annals of Oncology · 2019 · 17 citations

Medicine, Oncology, Pharmacotherapy +6